At $10.4 billion dollars, biotech giant Amgen's acquisition of Onyx is the fifth-largest biotech deal in history - and definitely won't be the last. This deal is a perfect illustration of why there’s so much money being made in biotech...
- Amgen (Nasdaq: AMGN) Deal Shows How to Find Biotech's Best Investments
- Unlocked: The Fastest-Growing Companies in America
- The 5 Fastest-Growing Companies in the S&P 500
IPOs are back, big time. Even unsexy companies are sprouting sweet IPO gains.
Take organic grocer Sprouts Farmers Market. It gained nearly 123% in its first day of trading Thursday - the best initial public offering debut since LinkedIn more than two years ago.
IPOs as diverse as Norwegian Cruise Line Holdings Ltd. and fast-casual dining chain Noodles & Co. have soared... The market has locked and loaded on about $4 billion in U.S. IPOs so far this year.
At that pace, companies "going public" would raise the most this year since at least 1999.
Welcome to the white-hot IPO market.
There's only one problem...
If you're not rich - you know, aren't one of those high-net-worth "accredited investors" (in essence, an insider or someone with a good buddy at an investment bank) - then you probably are watching from the sidelines. And that's why I can't wait to show this to you today, because you don't have to watch the Millionaire's Game anymore. You can finally play it.
Pick up some of these shares today, and you can win it, too. Big...
One of the best indicators that a company will have future growth is the strength of its top line number - revenue.
Growing revenue gives companies more access to capital, enabling them to reinvest in their business and reward shareholders through returns and dividends.
On the other hand, if a company struggles to generate sales, it's often a good reason to dump a stock.
That's why we've gone through the S&P 500 to bring you the fastest-growing companies based on last quarter's year-over-year sales growth.